TABLE 2.
Treatment Characteristics for Patients in the Combined and Surgical Cohorts
| Combined Cohort (n = 11) | Surgical Cohort (n = 10) | P | |
|---|---|---|---|
| Operative management | |||
| No. debridements | |||
| Mean (range) | 2.3 (1–4) | 2.6 (1–3) | 0.71 |
| Defect size, cm2 | |||
| Mean (range) | 56 (24–225) | 48.5 (18–90) | 0.49 |
| Negative pressure (VAC) therapy (%) | 21 (72) | 18 (60) | 0.89 |
| Interval from excision to DPC, d | |||
| Mean (range) | 4.1 (2–10) | 4.2 (2–12) | 0.76 |
| Biologic therapy | |||
| Infliximab/Ustekinumab | 8/3 | N/A | |
| Time from closure to initiation of biologic therapy, d | |||
| Mean (range) | 16 (14–20) | N/A | |
| Duration of biologic therapy, mo | |||
| Mean (range) | 10.5 (6–15)* | N/A | |
| Follow-up, mo | |||
| Mean (range) | 18 (6–31) | 20.5 (4–36) | 0.81 |
*
Four patients remained on biologic therapy at the time of final follow-up. DPC indicates delayed primary closure; N/A, Not Applicable, VAC, vacuum-assisted closure.